267 related articles for article (PubMed ID: 27576445)
1. Short Cationic Antimicrobial Peptides Display Superior Antifungal Activities toward Candidiasis and Onychomycosis in Comparison with Terbinafine and Amorolfine.
Stensen W; Turner R; Brown M; Kondori N; Svendsen JS; Svenson J
Mol Pharm; 2016 Oct; 13(10):3595-3600. PubMed ID: 27576445
[TBL] [Abstract][Full Text] [Related]
2. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Seidl HP; Jäckel A; Müller J; Schaller M; Borelli C; Polak A
Mycoses; 2015 Oct; 58(10):610-9. PubMed ID: 26334024
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.
Tatsumi Y; Yokoo M; Senda H; Kakehi K
Antimicrob Agents Chemother; 2002 Dec; 46(12):3797-801. PubMed ID: 12435679
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis.
Rossi DC; Muñoz JE; Carvalho DD; Belmonte R; Faintuch B; Borelli P; Miranda A; Taborda CP; Daffre S
BMC Microbiol; 2012 Mar; 12():28. PubMed ID: 22394555
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
7. Effect of Lamisil and azole antifungals in experimental nail infection.
Richardson MD
Dermatology; 1997; 194 Suppl 1():27-31. PubMed ID: 9154398
[TBL] [Abstract][Full Text] [Related]
8. Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation.
Schaller M; Walker B; Nabhani S; Odon A; Riel S; Jäckel A
Mycoses; 2024 Mar; 67(3):e13710. PubMed ID: 38414346
[TBL] [Abstract][Full Text] [Related]
9. Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Ng SM; Yap YY; Cheong JW; Ng FM; Lau QY; Barkham T; Teo JW; Hill J; Chia CS
J Pept Sci; 2017 Mar; 23(3):215-221. PubMed ID: 28105725
[TBL] [Abstract][Full Text] [Related]
10. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.
Evans EG
J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S32-36. PubMed ID: 9594934
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
Feng X; Xiong X; Ran Y
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28097731
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization and antifungal activity of a novel formulated nanocomposite containing Indolicidin and Graphene oxide against disseminated candidiasis.
Farzanegan A; Roudbary M; Falahati M; Khoobi M; Gholibegloo E; Farahyar S; Karimi P; Khanmohammadi M
J Mycol Med; 2018 Dec; 28(4):628-636. PubMed ID: 30126717
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.
Bradley MC; Leidich S; Isham N; Elewski BE; Ghannoum MA
Mycoses; 1999; 42 Suppl 2():105-10. PubMed ID: 10865915
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
Schaller M; Borelli C; Berger U; Walker B; Schmidt S; Weindl G; Jäckel A
Med Mycol; 2009 Nov; 47(7):753-8. PubMed ID: 19888808
[TBL] [Abstract][Full Text] [Related]
15. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis.
Seebacher C
Mycoses; 2003 Dec; 46(11-12):506-10. PubMed ID: 14641625
[TBL] [Abstract][Full Text] [Related]
16. Fungicidal effect of three new synthetic cationic peptides against Candida albicans.
Nikawa H; Fukushima H; Makihira S; Hamada T; Samaranayake LP
Oral Dis; 2004 Jul; 10(4):221-8. PubMed ID: 15196144
[TBL] [Abstract][Full Text] [Related]
17. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.
Haria M; Bryson HM
Drugs; 1995 Jan; 49(1):103-20. PubMed ID: 7705210
[TBL] [Abstract][Full Text] [Related]
18. Antifungal agents: an overview. Part II.
Gupta AK; Sauder DN; Shear NH
J Am Acad Dermatol; 1994 Jun; 30(6):911-33; quiz 934-6. PubMed ID: 7619094
[TBL] [Abstract][Full Text] [Related]
19. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis.
Warshaw EM; Nelson D; Carver SM; Zielke GR; Webster N; Lederle FA; Fett DD
Int J Dermatol; 2005 Sep; 44(9):785-8. PubMed ID: 16135154
[No Abstract] [Full Text] [Related]
20. Open label trial of the efficacy and tolerability of Lamisil (Terbinafine) 500 mg once daily in the treatment of onychomycosis due to candida.
Zaidi Z; Jafri N; Khan K; Hasan P; Kapadia N
J Pak Med Assoc; 1996 Nov; 46(11):258-60. PubMed ID: 9000820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
